Exabis Library
Welcome to the e-CCO Library!
P537: Is anti-TNF therapeutic drug monitoring of value in IBD patients in clinical remission?
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P537: Prevalence of post-COVID-19 vaccination IBD flare-ups: a single-center prospective study.
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P537: Steroid use in patients with immune checkpoint inhibitor colitis
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P537: The impact of early disease control with vedolizumab on surgery rates among patients with Crohn’s disease: a post-hoc analysis of the GEMINI trials
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P538 Pregnancy outcomes in women with psoriasis, psoriatic arthritis, Crohn’s disease and ulcerative colitis treated with ustekinumab
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P538: Can enteral polymeric diet change the post-surgical outcome in Crohn's disease patients? A pilot study
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P538: Enteral nutrition for the maintenance of remission in adults with inactive Crohn’s disease: A meta-analysis
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P538: Implementation of Kono-S anastomosis as a new standard of surgical care
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P538: Suboptimal disease control is common in patients with Crohn's perianal fistulas with capacity to optimise medical and surgical treatment in real-world experience: A cross-sectional analysis of baseline disease characteristics in the FINESS study
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P538: The reliability of patient performed fecal calprotectin testing
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P538: Vedolizumab is effective in real life paediatric inflammatory bowel disease: report from the prospective, multi-centre VEDOKIDS cohort study
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P539 Assessment of age as a risk factor for adverse events in patients from the tofacitinib ulcerative colitis clinical programme
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P539: COVID-19 is Associated with Long-term Elevated Fecal Calprotectin Levels in Patients with Crohn's Disease but not in Ulcerative Colitis.
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P539: Does a change in therapeutic approach modify outcome in IBD patients? A comparison between two cohorts 2004–2007 and 2010–2013
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P539: Impact of a multi-disciplinary team meeting for managing inflammatory bowel disease patients: professional practice analysis based on 869 cases
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P539: Patient Preferences for Inflammatory Bowel Disease Treatments: Development of a European Preference Survey using a Discrete Choice Experiment
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P539: Transcriptional changes in mucosal inflammation associated with an autoimmune protocol diet for ulcerative colitis
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P539: Unmet needs in advanced therapy-naïve (ATN) and advanced therapy-experienced (ATE) moderate-to-severe (mod-sev) ulcerative colitis (UC) patients in the United States (US)
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P540 GB004, a novel prolyl hydroxylase inhibitor for inflammatory bowel disease, leads to gut-targeted HIF-1α pathway engagement in a multiple-dose study in healthy subjects
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P540: Early response as a prognostic factor for vedolizumab: A real-life experience from a single Italian tertiary centre
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM